SANTONI, ADELE
 Distribuzione geografica
Continente #
EU - Europa 1.383
NA - Nord America 1.073
AS - Asia 661
SA - Sud America 128
AF - Africa 52
OC - Oceania 3
Totale 3.300
Nazione #
US - Stati Uniti d'America 1.031
RU - Federazione Russa 415
IT - Italia 235
SG - Singapore 199
IE - Irlanda 180
CN - Cina 160
DE - Germania 147
GB - Regno Unito 121
BR - Brasile 107
VN - Vietnam 81
FI - Finlandia 79
FR - Francia 73
HK - Hong Kong 58
SE - Svezia 55
CA - Canada 29
IN - India 28
ZA - Sudafrica 28
KR - Corea 25
PK - Pakistan 17
PL - Polonia 17
NL - Olanda 14
BD - Bangladesh 12
IR - Iran 11
CZ - Repubblica Ceca 10
IQ - Iraq 9
AR - Argentina 8
EG - Egitto 8
ES - Italia 8
JP - Giappone 8
MX - Messico 8
AT - Austria 6
SA - Arabia Saudita 6
UA - Ucraina 6
UZ - Uzbekistan 6
CO - Colombia 5
ID - Indonesia 4
MA - Marocco 4
TR - Turchia 4
AU - Australia 3
BO - Bolivia 3
KH - Cambogia 3
MY - Malesia 3
NG - Nigeria 3
NP - Nepal 3
PH - Filippine 3
PT - Portogallo 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CH - Svizzera 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EC - Ecuador 2
ET - Etiopia 2
GR - Grecia 2
KE - Kenya 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LK - Sri Lanka 2
OM - Oman 2
PY - Paraguay 2
AL - Albania 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
IL - Israele 1
JO - Giordania 1
LT - Lituania 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 3.300
Città #
Dallas 234
Dublin 179
Singapore 126
Munich 114
Ashburn 110
Moscow 109
Southend 81
Santa Clara 67
Helsinki 63
San Jose 61
Hong Kong 54
Chandler 48
Hefei 46
Siena 44
Beijing 39
Los Angeles 34
Fairfield 33
New York 33
Florence 27
Johannesburg 26
Ho Chi Minh City 25
Lauterbourg 25
Hanoi 24
Seoul 24
Milan 22
The Dalles 22
Council Bluffs 20
Seattle 19
Princeton 18
Woodbridge 16
Shanghai 15
Rome 14
Houston 13
Warsaw 13
Wilmington 13
Cambridge 11
Chennai 10
Turin 10
Washington 10
Buffalo 9
Frankfurt am Main 9
London 9
Portsmouth 9
São Paulo 9
Toronto 9
Turku 9
Brooklyn 8
Montreal 8
Denver 7
Messina 7
Orem 7
Redondo Beach 7
Tokyo 7
Bengaluru 6
Chicago 6
Fremont 6
Tashkent 6
Baghdad 5
Haiphong 5
Lappeenranta 5
San Diego 5
San Francisco 5
Stockholm 5
Atlanta 4
Brno 4
Da Nang 4
Düsseldorf 4
Fano 4
Guarulhos 4
Mumbai 4
Nuremberg 4
Olomouc 4
Phoenix 4
Rio de Janeiro 4
San Mateo 4
Abuja 3
Ann Arbor 3
Biên Hòa 3
Brescia 3
Buscate 3
Dammam 3
Genova 3
Grosseto 3
Kensington 3
La Paz 3
Montecatini Terme 3
Morrinhos 3
Ottawa 3
Paris 3
Phnom Penh 3
Poplar 3
Porto Alegre 3
Querétaro 3
Ribeirão Preto 3
Shenzhen 3
Vancouver 3
Abidjan 2
Alexandria 2
Amsterdam 2
Aracaju 2
Totale 2.139
Nome #
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 291
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 288
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 225
A fatal unsuspected case of acquired A hemophilia. Misleading role of therapy with acetylsalicylic acid? 217
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopenia 213
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 204
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 200
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 192
Anti CD38 monoclonal antibodies for multiple myeloma treatment 190
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden 177
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 170
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) 160
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 152
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 146
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 139
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia 124
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis 122
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 67
IDENTIFICATION OF LEUKEMIC STEM CELLS IN AML PATIENTS BY USING NEXT-GENERATION FLOW: A PERSONALIZED BIOMARKER OF PROGNOSIS AND PROGRESSION 48
Allogeneic hematopoietic stem cell transplantation despite severe Fusarium solani infection in a lung transplanted patient. A case report 21
Reply to “Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!” 21
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 6
Totale 3.373
Categoria #
all - tutte 11.480
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.480


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 11 2 15
2021/2022167 4 22 14 16 4 5 5 7 8 17 29 36
2022/2023257 12 38 30 27 8 31 4 20 16 4 54 13
2023/2024429 16 13 42 29 36 99 123 14 9 21 7 20
2024/2025775 17 19 78 34 69 63 81 74 95 42 83 120
2025/20261.600 101 199 216 241 381 64 155 44 87 112 0 0
Totale 3.373